Genmab A/S ADS (GMAB)

FairStock Score: 67/100 — STEADY

Key Financials

Strengths

• Generates $1.1 billion in annual free cash flow (6.4% yield on market cap)
• Solid return on equity of 17.5% above cost of capital
• Revenue growth of 42.3% demonstrates strong top-line momentum

Concerns

• Weak Piotroski F-Score of 0/9 suggests deteriorating financial quality across multiple dimensions

AI Analysis

Genmab A/S ADS is a mid-cap healthcare company valued at $16.7 billion. The business generates $3.7 billion in annual revenue with a 5.3% net margin and $1.1 billion in free cash flow. From a quality standpoint, Genmab shows weak Piotroski F-Score of 0/9 signaling deteriorating fundamentals and Altman Z-Score of 2.0 in the grey zone. On valuation, the stock is reasonably priced at 17.5x earnings, with offers a 53% margin of safety vs Graham Number of $57. Growth dynamics show revenue growing at 42.3% and profit growth of -93.7%. Our composite FairStock Score of 67/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Genmab's 42% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $1.1 billion in annual free cash flow (6.4% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer